Is Jasper Therapeutics, Inc. (JSPR) a Buy, Sell, or Hold?
NASDAQ : JSPR
Jasper Therapeutics, Inc.
$0.9572 USD
$0.16 (19.74%)
- Volume
- 993.92K
- Average Volume
- 1.14M
- Market Capitalization
- $15.56M
- P/E Ratio
- -0.28
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $3.14
- Year Low
- $0.32
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.26
Company Overview
NASDAQ
Jeetinder Singh Mahal
Biotechnology
Healthcare
JSPR
22
US
USD
Liquidity Metrics
0.22
2.26
2.26
1.57
0.00
Sales & Valuation
-$
0.00
5.40
-0.23
-3.59
Profitability
-$3.95
-$75.8M
0.00%
0.00%
-523.04%
-263.09%
P/E Metrics
-0.28
-0.01
-0.01
Analyst Price Target & Rating
$3.00
$3.00
$3.00
2/5
13 Analysts
-68.09%
Financial Health Scores
-28.64
0/9
$11.3M
$21.18M
$17.78M
-$55.73M
Key Metrics (TTM)
-$394.7K
0.00
0.01
2.26
-523.04%
-564.18%
-363.73%
-530.11%
-42392 days
Company Executives
| Name | Title |
|---|---|
| Jeetinder Singh Mahal | President, Chief Executive Officer & Director |
| Matthew E. Ros | Chief Operating Officer |
| Herbert C. Cross | Chief Financial Officer & Corporate Secretary |
| Thomas G. Wiggans | Executive Chairman |
| Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director |
| Luca Di Noto | Senior Vice President of Technical Operations |
| Alex Gray | Head of Investor Relations |
| Matthew Ford | Senior Vice President of Human Resources |
Poll Results
No votes yet today — be the first to share your view!
About Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California. ...
Jasper Closes Kira Deal, Extends Cash Runway
2026-07-17 13:08:07
Jasper Therapeutics Inc. (NASDAQ:JSPR) on Thursday said it completed its all-stock acquisition of Kira Pharmaceuticals, bringing the two biotechnology companies together to advance a unified pipeline of therapies targeting immune-mediated and autoantibody-driven diseases.
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
2026-07-16 17:15:00
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders
Bears are Losing Control Over Jasper Therapeutics (JSPR), Here's Why It's a 'Buy' Now
2026-06-03 10:56:17
Jasper Therapeutics (JSPR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
2026-06-01 08:00:00
REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value.
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-14 16:05:00
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.
Frequently Asked Questions
-
What is the current Jasper Therapeutics, Inc. (JSPR) stock price?
-
Jasper Therapeutics, Inc.(NASDAQ:JSPR) stock price is $0.9572 in the last trading session. During the trading session, JSPR stock reached the peak price of $3.14 while $0.315 was the lowest point it dropped to. The percentage change in JSPR stock occurred in the recent session was 19.74% while the dollar amount for the price change in JSPR stock was $0.16.
-
JSPR's industry and sector of operation?
-
The NASDAQ listed JSPR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of JSPR?
-
Jeetinder Singh Mahal | President, Chief Executive Officer & Director
Matthew E. Ros | Chief Operating Officer
Herbert C. Cross | Chief Financial Officer & Corporate Secretary
Thomas G. Wiggans | Executive Chairman
Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director -
How many employees does JSPR have?
-
Number of JSPR employees currently stands at 22. JSPR operates from 2200 Bridge Pkwy, Redwood City, CA 94065, US.
-
Link for JSPR official website?
-
Official Website of JSPR is: https://jaspertx.com
-
How do I contact JSPR?
-
JSPR could be contacted at phone #650 549 1400 and can also be accessed through its website. JSPR operates from 2200 Bridge Pkwy, Redwood City, CA 94065, US.
-
How many shares of JSPR are traded daily?
-
The average number of JSPR shares traded daily for last 3 months was 1.14M.
-
What is the market cap of JSPR currently?
-
The market value of JSPR currently stands at $15.56M with its latest stock price at $0.9572